June 6th 2020, 7:00pm
Presented by Mark Agulnik, MD from Northwestern University, please join us on July 8, 2020 at 8 PM EDT for a presentation on an FDA-approved treatment option for use in patients with advanced CSCC.
June 4th 2020, 11:51pm
In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.
June 4th 2020, 7:30pm
Axel Hauschild, MD, PhD, discusses the 5-year findings from the COMBI-AD trial.
May 31st 2020, 5:22pm
In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.
May 30th 2020, 11:23pm
The combination of encorafenib and binimetinib demonstrated continuing benefit in overall survival and progression-free survival for patients with BRAF V600–mutant melanoma.
May 30th 2020, 9:12pm
Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected, stage III BRAF V600E/K-mutant melanoma.
May 30th 2020, 7:36pm
AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.
May 13th 2020, 6:06pm
Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.
May 13th 2020, 2:05pm
May 6th 2020, 6:37pm
Alain Algazi, MD, discusses the SWOG S1320 trial further, the future of intermittent dosing in melanoma, and future clinical trials in the field.
